
    
      It will be enrolled 250 participants of both sexes within two weeks after diagnosed
      cryptogenic stroke and/or TIA at Akershus University Hospital, Oslo area, Norway.

      Evaluation of participants' comorbidity with CHADS2-VASc score, ECG, Holter ECG,
      echocardiography, detection of biochemical cardiac markers and screening for obstructive
      sleep apnea syndrome will be performed. All participants will be monitored with a continuous
      cardiac rhythm during one year by implantation of implantable cardiac rhythm monitors (ICRM).
      All patients without high bleeding risk will get prescribed oral anticoagulants (OAC) after
      detection of PAF.

      A biobank will be established in order to store the sampled biological material.
    
  